6th Annual Genome Editing Congress04 - 06 November 2020, GMT (UTC+0)

With gene editing tools becoming advanced enough to realise therapeutic potential, decision-makers working in academia and pharma are looking to consolidate their techniques to facilitate disease modelling, drug development and clinical studies.

Last Year's Event Included...

Over 800 attendees representing internationally renowned academic institutions, research institutes and hospitals as well as global pharmaceutical organisations and leading biotech companies.

Over 30 case studies, presentations, panel discussions focused on the key issues in advanced genome editing technologies, utilizing gene editing in drug discovery & development and therapeutics case studies from the areas of cystic fibrosis, neurodegenerative diseases and immunological and congenital disorders.  

PLUS interactive opportunities including:

  • Panel Discussions
  • Pre-Event Webinars
  • Pre-Event Speaker Q&As and Spotlights

Agenda at a Glance

Pre-Event Deep Dive Sessions

  • Microbiome Methodologies
  • Single Cell Proteomics
  • Clinical Diagnostics & Precision Medicine Multi-Technology Session

Day One

  • Genome Editing Technologies & Techniques

Day Two

  • Genome Editing in Discovery & Development
  • Therapeutic Applications of Genome Editing

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST